A Phase I Dose-Escalation Study Evaluating the Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 30 Oct 2014
At a glance
- Drugs Neratinib (Primary) ; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms NSABP-FB8
- 07 Jul 2014 Status changed from active, no longer recruiting to completed asreported by ClinicalTrials.gov record.
- 11 Oct 2013 Planned end date changed from 1 Aug 2013 to 1 Feb 2014.as reported by ClinicalTrials.gov.
- 24 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Aug 2013 as reported by ClinicalTrials.gov.